Evaluation of Methods for Predicting Drug-drug Interactions by Monte Carlo Simulation

Drug Metabolism and Pharmacokinetics

Volumn 18, Issue 2, 2003, Pages 121-127

  Kato, Motohiro ^a   Tachibana, Tatsuhiko ^a   Ito, Kiyomi ^b   Sugiyama, Yuichi ^c  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

drug discovery and development; drug drug interaction; inhibition constant; Monte Carlo method; PBPK model

Indexed keywords

EID: 85008414650     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.18.121     Document Type: Article

References (19)

1. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y.: Prediction of pharmacokinetic alterations caused by drug-drug interactions. Pharmacol. Rev., 50: 387-411 (1998).
2. Lin, J. H. and Lu, A. Y. H.: Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet., 35: 361-390 (1998).
3. Tucker, G. T., Houston, J. B. and Huang, S. M.: Optimizing drug development: Strategies to assess drug metabolism Wtransporter interaction potential-Toward a concensus. Pharm. Res., 18: 1071-1080 (2001).
4. Kuhlmann, J., MuCk, W.: Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Safety, 24: 715-725 (2001).
5. von Moltke, L. L., Greenblatt, D. J., Schimder, J., Wright, E. C., Harmatz, J. S. and Shader, R. J.: In vitro approaches to predicting drug interactions in vivo. Biochemical Pharmacology, 55: 113-122 (1998).
6. Bertz, R. J. and Granneman, G. R.: Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet., 32: 210-258 (1997).
7. Murray, M.: Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes. International Journal ofMolecular Medicine, 3: 227-238 (1999).
8. Rowland, M. and Martin, S. B.: Kinetics of drug-drug interactions. J. Pharmacokinet. Biopharm., 1: 553-567 (1973).
9. Wilkinson, G. R.: Clearance approaches in pharmacology. Pharmacol. Rev., 39: 1-47 (1987).
10. Ito, K., Chiba, K., Horikawa, M., Ishigami, M., Mizuno, N., Aoki, J., Gotoh, Y., Iwatsubo, T., Kanamitsu, S., Kato, M., Kawahara, I., Niinuma, K., Nishino, A., Sato, N., Tsukamoto, Y., Ueda, K., Itoh, T. and Sugiyama, Y.: Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS Pharm Sci, 4: article 25 (2002).
11. Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W. and Gilman, G. A., (eds.): Goodman and Gilmans's The Pharmacological Basis of Therapeutics 9th ed., New York, McGraw-Hill, 1996, pp 1712.
12. Davis, A. M., Webborn, P. J. H. and Salt, D. W.: Robust assessment of statistical significance in the use of unbound/intrinsic pharmacokinetic parameters in quantitative structure-pharmacokinetics relationships. Drug Metab. Disp., 28: 103-106 (2000).
13. Smith D. A.: Physicochemical properties in drug metabolism and pharmacokinetics. In Van de Water-beemd, H., Testa, B. and Folkers, G. (eds.): in Computer-Assisted Lead Finding and Optimization vol 11, Basel, Verlag Helvetica Chimica Acta,, 1997, pp. 267-276.
14. Toon, S. and Rowland, M.: Structure activity relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther., 225: 752-763 (1983).
15. Toon, S. and Rowland, M.: Quantitative structure pharmacokinetic activity relationships with some tetracyclines. Pharm. Pharmacol. Suppl. (Br Pharm Conf 31: 43P (1979).
16. Ministry of Health, Labar and Welfare: Methods of Drug Interaction Studies: Notification No. 813 of the Pharmaceutical Affair Bureau (2001).
17. Iwatsubo, T., Suzuki, H. and Sugiyama, Y.: Prediction of species differences (rats, dogs, humans) in the in vivo metabolic clearance of YM796 by the liver from in vitro data. J. Pharmacol. Exp. Ther., 283: 462-469 (1997).
18. Naritomi, Y., Terashita, S., Kimura, S., Suzuki, A., Kagayama, A. and Sugiyama, Y.: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos., 29: 1316-1324 (2001).
19. Izumi, T., Enomoto, S., Hosiyama, K., Sasahara, K., Shibukawa, A., Nakagawa, T., and Sugiyama, Y.: Prediction of the human pharmacokinetics of troglita-zone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J. Pharmacol. Exp. Ther., 277: 1630-1641 (1996).